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Abstract
Background: Coccidioidomycosis or Valley fever is caused by a highly virulent fungal pathogen: Coccidioides
posadasii or immitis. Vaccine development against Coccidioides is of contemporary interest because a large number
of relapses and clinical failures are reported with antifungal agents. An efficient Th1 response engenders protection.
Thus, we have focused on developing a dendritic cell (DC)-based vaccine for coccidioidomycosis. In this study, we
investigated the immunostimulatory characteristics of an intranasal primary DC-vaccine in BALB/c mouse strain that
is most susceptible to coccidioidomycosis. The DCs were transfected nonvirally with Coccidioides-Ag2/PRA-cDNA.
Expression of DC-markers, Ag2/PRA and cytokines were studied by flow cytometry, dot-immunoblotting and
cytometric bead array methods, respectively. The T cell activation was studied by assessing the upregulation of
activation markers in a DC-T cell co-culture assay. For trafficking, the DCs were co-transfected with a plasmid DNA
encoding HSV1 thymidine kinase (TK) and administered intranasally into syngeneic mice. The trafficking and
homing of TK-expressing DCs were monitored with positron emission tomography (PET) using
18F-FIAU probe.
Based on the PET-probe accumulation in vaccinated mice, selected tissues were studied for antigen-specific
response and T cell phenotypes using ELISPOT and flow cytometry, respectively.
Results: We found that the primary DCs transfected with Coccidioides-Ag2/PRA-cDNA were of immature
immunophenotype, expressed Ag2/PRA and activated naïve T cells. In PET images and subsequent biodistribution,
intranasally-administered DCs were found to migrate in blood, lung and thymus; lymphocytes showed generation
of T effector memory cell population (TEM) and IFN-g release.
Conclusions: In conclusion, our results demonstrate that the intranasally-administered primary DC vaccine is
capable of inducing Ag2/PRA-specific T cell response. Unique approaches utilized in our study represent an
attractive and novel means of producing and evaluating an autologous DC-based vaccine.
Background
Coccidioidomycosis or Valley fever is caused by a
dimorphic fungus: Coccidioides posadasii or C. immitis.
Due to high virulence, both of the Coccidioides species:
C. posadasii and C. immitis have been included in the
National Institute of Allergy and Infectious Disease
(NIAID)’s list of Biodefense Pathogens and in the Center
for Disease Control (CDC)’s list of Select Agents. Cocci-
dioidomycosis is endemic in areas of Southwest US,
Mexico and several countries of South America. The
infection is initiated by inhalation of air-borne arthroco-
nidia. An insufficient cell-mediated immunity promotes
the formation of parasitic-phase endosporulating spher-
ule structures in lung and hematogenous spread of
organisms into non-pulmonary organs leading to more
severe disseminated coccidioidomycosis [1]. The disse-
minated infection causes increased morbidity and mor-
tality, specifically in people with immunocompromised
conditions. African-Americans, Fillipinos and pregnant
women are also at a high risk of developing dissemi-
nated coccidioidomycosis [2]. Among all the endemic
fungal infections, coccidioidomycosis has generated a
great interest in vaccine development because a prior
infection engenders immunity, a large number of
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conventional antifungal-agents, the disease produces a
significant burden of morbidity, the rate of infection is
increasing in endemic areas [3], and most importantly,
Coccidioides poses a risk of bioterrorism [4].
As is evident from the studies in patients with disse-
minated coccidioidomycosis and animal models, the
susceptibility to the disease is related to defective T cell-
immune responses [5]. An effective antigen-presentation
by antigen-presenting immune cells is a critical step in
engendering protective T cell responses. Among a vari-
ety of cells, the dendritic cells (DCs) are the most potent
antigen-presenting cells. As such, suppressed DC
responses are evidently associated with defective T cell
responses in patients with disseminated coccidioidomy-
cosis [6,7], and in susceptible mouse strains, such as
BALB/c mouse strain [8,9]. Unlike other antigen-pre-
senting immune cells, DCs migrate to lymph nodes, and
activate naïve immune cells including T cells. Based on
this property, DC-based vaccines have been evaluated in
animal models of a variety of infections as well as can-
cer. Some of the DC-based vaccines are currently under-
going pre-clinical/clinical trials for AIDS and different
types of cancer [10-19]; a therapeutic DC-vaccine (Sipu-
leucel-T) was recently approved by Food and Drug
Administration (FDA) for the management of prostate
cancer [20,21]. Our laboratory’s focus is on developing a
DC-based vaccine for coccidioidomycosis [8,22,23].
The success of a DC-based vaccine depends on multi-
ple factors, including type of antigen, loading efficiency
of DCs with antigen, route of administration, trafficking,
and the ability to express protective antigen in vivo, inter-
act with naïve immune cells and activate effector immune
cells. In a previous study, we reported a DC-vaccine pre-
pared by genetically transfecting the immortalized mye-
loid JAWS II DCs (ATCC, VA) with a plasmid DNA
encoding Coccidioides-Ag2/PRA-cDNA (a potent protec-
tive epitope of Coccidioides species) [22]. Furthermore,
we showed its protective efficacy as a prophylactic vac-
cine in reducing the fungal load in syngeneic C57BL6
mouse strain that is moderately susceptible to C. posada-
sii infection [23]. The study provided a proof-of-principle
that the non-virally, genetically-transfected DCs can help
reduce the fungal load [5]. Based on these initial results
[8,22-24], we have now prepared a vaccine using primary
myeloid DCs. Besides the possibility of the altered immu-
nostimulatory characteristics of primary DCs in different
mouse strain, it is also important to note that an immor-
talized DC cell line may not be used in clinical scenario.
It is also expected that an autologous primary DC-based
vaccine will be easily translatable and more feasible as a
therapeutic vaccine. Here we used BALB/c mouse strain
because it is extremely susceptible to coccidioidomycosis,
and Coccidioides- i n f e c t e dB A L B / cm i c ep r e s e n t
immunological features (less IFN-g, suppressed DC
responses) similar to those observed in patients with dis-
seminated disease [5,8]. Since the efficacy and functions
of DC-vaccination depends primarily on DC-phenotypes,
it is important to evaluate the phenotype, stability of anti-
gen expression, in vivo trafficking, antigen presentation
and T cell stimulating potential of primary DCs. With
these criteria in mind, a DC-vaccine was prepared using
BALB/c mice-derived primary DCs by genetically-trans-
fecting with a plasmid DNA containing Coccidioides-
Ag2/PRA-cDNA; the phenotype and antigen-presenta-
tion were studied. To enable in vivo monitoring of DCs
by PET imaging, the DCs were co-transfected with HSV1
thymidine kinase cDNA. The image-derived biodisposi-
tion of administered DCs assisted in focusing on select
organs for further evaluation of memory T cell popula-
tions and Ag2/PRA-specific responses.
Results
Morphology and Phenotype of primary DCs and JAWS II
DCs
The yield of primary DCs of BALB/c and C57BL6 mice
on day 2 and day 4, varied from 6%-20% of total har-
vested bone marrow cells. More than 98% of DCs
remained viable on day 2 and day 4 of harvesting. Mor-
phologically, 2dDC and 4dDC as well as JAWS II cells
showed immature phenotype. There was no difference
between the primary DCs originating from either
C57BL6 or BALB/c mouse strains. Similar to the JAWS
II DCs, the primary DCs did not possess tentacles or
dendrite-like structures (Figure 1). When the cells were
allowed to continue differentiating for 13 days in pre-
sence of GM-CSF and IL-4, the DCs developed typical
morphology of mature DCs characterized by the appear-
ance of dendrite structures on their cell surface.
The immunophenotype of harvested primary DCs was
confirmed by flow-cytometry. The primary DCs were
found to be negative for CD14 (a macrophage marker),
CD3 (a T cell marker) and CD45RA (a B cell marker), and
this negativity continued through the duration of the
experiment. We confirmed the myeloid or plasmacytoid
nature of primary DCs by staining with fluorochrome-con-
jugated antibodies: SiglecH, PDCA1, 120G8, CD62L, B220
and CD11c. As evident from negative or negligible staining
for SiglecH, CD62L, B220, the primary DCs and JAWS II
DCs were mainly of myeloid phenotype. At the same time,
the primary DCs and JAWSII DCs were very low positive
for PDCA1 and 120G8 markers demonstrating again that
they were not of plasmacytoid type (Figure 2).
The JAWS II DCs as well as 2dDC and 4dDC showed
positive staining for CD11c, MHC class II and T cell co-
stimulatory molecules (CD40, CD80, CD86). However, we
observed that compared to JAWS II DCs, the expression
of these cell surface markers on primary 2dDCs increased
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(Figure 3). Based on these observations, we decided to use
2dDCs for downstream experiments.
Immunophenotype and transgene expression in
transfected DCs
Next we investigated whether the primary DCs trans-
fected with plasmid DNAs encoding transgenes
expressed the respective proteins, and maintained
their immunophenotype. The DNA transfection effi-
ciency of primary DCs ranged from 30-40% which is
within 10% of the transfection efficiencies previously
reported by us in JAWS II DCs [22] (Figure 4A). The
viability of primary DCs after transfection ranged
from 52% (versus 55% nontransfected)-81% (versus
73% nontransfected; Figure 4B) as compared to 68%
for JAWS II DCs [22]. No significant changes were
observed in the cell-surface expression CD11c, MHC
class II, CD40, CD80 and CD86 by primary DCs post-
transfection (Figure 5). The morphology also
remained unaltered (not shown). Similarly, the pri-
mary DCs co-transfected with pVR1012-Ag2/PRA-
cDNA and pVR1012-TK did not show any changes in
cell-surface expression of DC-markers or morphology
(data not shown).
Figure 1 The morphology of (A) JAWS II DCs, and primary
murine DCs derived from (B) BALB/c and (C) C57BL6 mice
shows identical features. The primary DCs were harvested on days
2 (2dDC) and 4 (4dDC) of culturing bone marrow cells. The cells
were air-dried on a glass slide, stained with Wright-Giemsa stain,
and photomicrographed at 400X using a Leica light microscope.
Figure 2 The flow cytometric histograms of JAWS II DCs and primary murine DCs derived from BALB/c and C57BL6 mice.T h eD C s
were stained with fluorochrome-conjugated antibodies specific to SiglecH, PDCA1, B220, CD62L, 120G8 antigens. The cell debris was gated-out
and histogram charts were plotted. The filled histograms are of isotype-control antibody-stained cells. The mean fluorescent intensity (MFI)
values were determined for the cells under the bar (⊓) region. The values within the charts indicate the MFI values for cells stained with isotype-
control antibody (I), or antigens-specific antibodies (M). The results are from one representative experiment conducted thrice.
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specific to DC-markers. The primary DCs were harvested on days 2 (2dDC) and 4 (4dDC) of culture and stained with fluorochrome-conjugated
antibodies specific to MHC class II, CD11c, CD40, CD80, CD86 antigens. The cell debris was gated-out and histogram charts were plotted. The
filled histogram charts are of cells stained with isotype-control antibody. The mean fluorescent intensity (MFI) values were determined for the
cells under the bar (⊓) region. The values within the charts indicate the MFI values for the cells stained with isotype-control antibody (I), or
antigens-specific antibodies (M). The results are from one representative experiment conducted thrice.
Figure 4 (A) Photomicrographs of primary DCs after nonviral genetic transfection. The top panel is a fluorescence photomicrograph of
primary DCs showing GFP-expression (in green) after 24 h of transfection. The bottom panel is a photomicrograph of cells in the same field
under bright-field filter. (B) Flow cytometric histograms of transfected primary DCs showing the effect of transfection on their viability. The
transfected (dotted line) and nontransfected (solid line) primary DCs after two days of culture were stained with propidium iodide. The values
indicate % viable nontransfected (NT) and transfected (T) cells under the marked region. The results are from one representative experiment
conducted more than three times.
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TK proteins by dot-immunoblotting of cell-lysate of pri-
mary DCs co-transfected with pVR1012-Ag2/PRA-
cDNA and pVR1012-TK (Figure 6).
Cytokine secretion by transfected DCs
After characterizing the transfected primary DCs for
their phenotype, we measured the levels of various cyto-
kines in cell-free supernatants. No significant changes
were observed in secreted amounts of TNF-a,I L - 6 ,I L -
12p70 and IL-10 (Figure 7).
Primary DCs transfected with pVR1012-Ag2/PRA-cDNA
induce activation of both CD4+ and CD8+ T lymphocytes
The primary goal of DC-vaccines is to stimulate lym-
phocyte-mediated immunity. Therefore, we investigated
whether the transfected primary DCs are capable of
activating homologous lymphocytes in vitro.W eh a r -
vested cells after 24 h of DC-lymphocyte co-culture for
flow cytometric analysis. The cells were stained with
fluorochrome-conjugated antibodies against CD4, CD8
(T cell markers), CD25 and CD69 (T cell activation-spe-
cific markers) and analyzed by 4-color flow cytometry.
Figure 6 The expression of transgenes-encoded Coccidioides-Ag2/PRA and TK antigens by genetically-transfected primary DCs.T h e
cell-lysates were prepared after 24 h of transfection, and dot-immunoblotting was performed with Ag2/PRA and TK-specific antibodies. Left
Panel: An Ag2/PRA dot-immunoblot of 5 μg cell-lysate protein from nontransfected (A), transfected primary DCs (B), and 0.2 μg recombinant
Ag2/PRA protein (C). Right panel: A TK Dot-immunoblot of 1 μg cell-lysate protein from nontransfected (A) and transfected DCs (B). Results are
from one experiment representative of more than three experiments.
Figure 5 Immunophenotype of primary DCs derived from (A) BALB/c and (B) C57BL6 mice, does not change after nonviral genetic
transfection. The 2dDC were transfected with pVR1012-Ag2/PRA plasmid DNA. After 24 h of transfection, the cells were stained with
fluorochrome-conjugated antibodies specific to MHC class II, CD11c, CD40, CD80, CD86 cell-surface antigens. The cell debris was gated-out and
histogram charts were plotted. The filled histogram charts are of cells stained with isotype-control antibody. The mean fluorescent intensity (MFI)
values were determined for the cells under the bar (⊓) region. The values within the charts indicate the MFI values for the nontransfected (NT,
black line) and transfected (T, green line) cells stained with antibodies specific to cell-surface antigens. The results are from one representative
experiment conducted thrice.
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DCs induce activation of both CD4+ and CD8+ T cells
(Figure 8). The induction of CD4+ and CD8+ T cells
was more pronounced with JAWS II DCs as compared
to BALB/c mice-derived primary DCs. The concavalin-
A activated splenic lymphocytes, DCs and lymphocytes
alone served as controls in these experiments (Figure 8).
Molecular imaging of primary DCs in a mouse model
After comparing the morphology, immunophenotype,
expression of the epitope, cytokine release and T cell-
stimulatory characteristics of pVR1012-Ag2/PRA-
cDNA-transfected primary DCs, we extended our study
to investigate the trafficking of primary DCs. We used
an HSV1-TK/
18F-FIAU system to image the distribution
of transfected primary DCs in a syngeneic mouse model.
Uptake of FIAU by JAWS II DCs transfected with
pVR1012-TK
First, we determined the HSV1-TK enzyme activity in
DC cell lysates based on their ability to phosphorylate
3H-Pencyclovir and
18F-FIAU substrates. We found that
the HSV1-TK-expressing primacy DCs phosphorylate
Figure 7 Cytokine (TNF-a, IL-12p70, IL-6 and IL10) levels (pg/ml) in cell-free supernatants of JAWS II and BALB/c mice derived primary
DCs after 24 h of genetic transfection with pVR1012-Ag2/PRA plasmid DNA. Results are from two experiments performed in triplicate.
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retained on the filter (Figure 9A-B). In cellular uptake
studies, we found that HSV1-TK-transfected JAWS II
DCs accumulated 3.8 folds more
18F-FIAU (Figure 9C).
Overall, the results suggest that HSV1-TK-transfected
DCs express an active TK enzyme that is capable of
phosphorylating and retaining
18F-FIAU substrate.
In vivo trafficking of primary DCs
For a successful DC-vaccine, it is important that the cells
traffic through or home into the areas where they can
present the antigens to naïve immune cells. Also, for an
adequate immune response the persistence of the DCs in
t h eb o d yf o rar e a s o n a b l et i m ep e r i o di sa l s oe s s e n t i a l .
Based on our previous published results [5], we intrana-
sally instilled about 1.5 million transfected primary DCs
in syngeneic mice. The instilled DCs were previously co-
transfected with Coccidioides-Ag2/PRA-cDNA and
pVR1012-TK. For the sake of simplicity, we will call the
group of mice instilled with Coccidioides-Ag2/PRA-
cDNA+pVR1012-TK plasmid transfected DCs as ‘DC-
vaccine group’; similarly, the mice that received DCs
transfected with vector plasmid DNA are called ‘Control’.
We studied the homing of DCs in live mice using PET-
CT imaging after 2 and 7 days of DC administration. Co-
registration of CT assisted in ascertaining anatomical
landmarks on the fused images (Figure 10). In both ‘DC-
vaccine’ as well as ‘Control’ groups on day 2, the images
did not show significant accumulation of radioactive
probe in the mice bodies. However, the PET images
acquired on 7
th day showed a significant accumulation of
18F-FIAU in lung and liver of ‘DC-vaccine’ as compared
to ‘Control group’ (Figure 10).
Biodistribution
On day 7 after the imaging was accomplished, the mice
were euthanized to collect various organs and fluid spe-
cimens. The organs were weighed and
18F-radioactivity
was counted. The biodistribution data confirmed the
PET-CT imaging results. There was significantly more
radioactivity in all the organs harvested from ‘DC-vac-
cine’ g r o u pa sc o m p a r e dt ot h e‘Control’ group. Due to
the difficulty in normalizing intestine- and stomach-
associated radioactivity by weight, we report the amount
of radioactivity in entire organ for these two organs.
While intestine did not show significant difference
between the two groups, stomach of ‘DC-vaccine’ group
accumulated higher amounts of radioactive probe than
the ‘Control’ group. The differences were more pro-
nounced in lung, thymus and blood (p < 0.005) in the
two groups (Figure 11).
Memory T cell phenotypes and Ag2/PRA-specific
response
After assessing the trafficking of the primary DC-vac-
cine, the T cell phenotypes were enumerated in lym-
phoid organs: spleen, thymus and lymph nodes. We
found that there was a slight decrease or no change in
number of CD4+ and CD8+ TCM and resting memory
cell populations, respectively, with simultaneous increase
Figure 8 In vitro T cell activation by Coccidioides-Ag2/PRA-cDNA transfected DCs. Panels (A) to (E) are BALB/c mice derived primary DCs,
and panels (F) to (I) are JAWS II DCs. The vector-plasmid DNA-transfected DCs (panels B and G) and Coccidioides-Ag2/PRA-cDNA transfected DCs
(panels C and H) were co-cultured with autologous splenic lymphocytes (1DC: 16 lymphocytes) for 24 h. The co-cultured cells were stained with
CD4, CD8, CD25 and CD69-specific antibodies. Panels (A) and (F) are dot plots for CD4+ and CD8+ cells. Representative dot-plots of splenic
lymphocytes (without DCs, as negative control) are shown in panels (D) and (I). Positive control included concavalin-treated splenic lymphocytes
(panel E). The values in each quadrant represent the percent number of CD4+ and CD8+ cells. Results are from one experiment representative
of three experiments performed in duplicate.
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Page 7 of 17Figure 9 In vitro thymidine kinase (TK) enzyme activity in JAWS II DC transfected with pVR1012-TK. The enzyme activity was measured in
the cell lysates using (A)
3H-pencycloviir, a conventional substrate for HSV1-TK enzyme, and (B)
18F-FIAU. The enzyme expression was confirmed
by studying the (C) uptake and retention of
18F-FIAU in the transfected cells after 4 h of adding the radiolabeled substrate. * p < 0.05 versus
nontransfected cells. Results shown here are mean (± SEM) of three experiments.
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node cells of vaccinated mice (Table 1). However, no
significant difference was observed in the number of
activated (CD25+ CD69+/-) cells.
Finally, we assessed the Ag2/PRA-specific T cell
response in lung, thymus and lymph node cells har-
vested from vaccinated mice. We found that a signifi-
cant number of lung and lymph node cells derived
from vaccinated mice secreted IFN-g in response to
Ag2/PRA challenge. However, there was no significant
difference in numbers of IL-4 and IL-17A-secreting
cells (Figure 12).
Discussion
Here, we present our recent data on primary bone-mar-
row-derived DCs genetically-transfected with
Figure 10 Fused positron emission tomography (PET) and computed tomography (CT) images of BALB/c mice intranasally instilled
with homologous primary DCs expressing HSV1-TK. The primary DCs were either co-transfected with pVR1012-Ag2/PRA-cDNA and pVR1012-
TK (labeled as DC-vaccine), or with vector plasmid DNA (labeled as Vector Control). The PET-CT imaging was performed after 7 days of cells
administration. About 2 h prior to imaging,
18F-FIAU (a substrate for HSV1-TK) was intravenously injected. Images are from one representative
mouse from each group. Six mice were included per group in three different experiments. In the second panels of each group, the whole body
images were zoomed to get closer view of
18F-FIAU accumulation (DC-migration) in thoracic area. A significant accumulation of
18F-FIAU was
observed in lung and liver of mouse injected with DCs expressing TK. Overall, the mice receiving DC-vaccine retained more
18F-FIAU radioactivity
than the Control mice. G.i.t (gastrointestinal tract).
Figure 11 The biodistribution of
18F-FIAU radioactive counts in major organs and fluid specimens of mice. The animal model and the
treatment are described in the figure 10 legend. Mice were euthanized after 140 min of injecting
18F-FIAU probe, and major organs and fluids
were harvested. The radioactive counts were corrected for physical decay of
18F (half-life 110 min), and normalized with tissue weight. The
intestine and stomach (insets) were calculated as percent injected dose for entire organ, because of the unavoidable problem related to the
presence of variable amounts of food and fecal matter significantly altering the tissue weight from one animal to the other. * p < 0.005, # p <
0.05 versus control (mice injected with DCs transfected with vector plasmid DNA). Results shown here are mean (SEM) of three experiments with
6 mice in each group.
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most susceptible to Coccidioides infection. Compared to
our earlier study on immortalized JAWS II DCs [23],
the transfection efficiency, viability and immunopheno-
type of primacy DCs was essentially identical. The trans-
fected primary DCs expressed almost similar levels of
GFP, Ag2/PRA and TK protein for at least up to 72 h of
transfection under in vitro conditions (Figures 4 and 6).
These results confirmed that a non-viral method is
equally efficacious for genetic transfection of primary
DCs as had been observed for immortalized JAWS II
cells [22,23]. Empirically, the generation of a protective
immune response by a DC-based vaccine depends
mainly on its phenotype and antigen-presenting func-
tions that may differ among the mouse strains
[13,25-28]. Therefore, we studied basic phenotypic char-
acteristics, antigen-presentation, in vivo trafficking of
primary DC-based vaccine in BALB/c mouse strain and
Table 1 Phenotype of splenic lymphocytes, thymocytes and lymph node cells (as percent CD4+ and CD8+ gated)
harvested from DC-vaccinated and control mice after 7 days of first immunization
Cells®
Groups ↓
CD4+ CD8+
CD25+
CD69+/- activated
T cells
CD44+ resting
memory
TEM
CCR-
CD62L hi
(lo)
TCM
CCR+
CD62L hi
CD25+
CD69+/- activated
T cells
CD44+ resting
memory
TEM
CCR-
CD62L lo
TCM
CCR+
CD62L
hi
Spleen
DC
vaccinated
0.88 87.3 39.9(56) 3.5 99.9 88.5 27.4 6.8
Control 1.27 92.6 56(38.2) 6.0 100 83.3 20.1 9.8
Thymocytes
DC
vaccinated
15.9 85.7 27.4(71) 0.51 100 53.8 69.3 3.5
Control 18.9 86.1 26.4(72) 0.53 100 56.8 69 3.7
Lymph
node
DC
vaccinated
1.72 88 64(33) 2.3 100 72.2 34.2 3.2
Control 1.51 90.2 67(29) 3.2 100 74.4 32 3.9
Results are from one representative experiment (n = 5 mice per group) performed thrice.
Figure 12 Assessment of Ag2/PRA-specific response in DC-vaccinated mice. The antigen-recall response was assessed by ELISPOT assay in
lymphocytes harvested from lung, thymus and lymph nodes of DC-vaccinated mice. The numbers of IFN-g, IL-4 and IL-17A-secreting
lymphocytes were counted by ELISPOT assay. The spots obtained were normalized per one million cells and subtracted those from control (mice
injected with DCs transfected with vector plasmid DNA). The results shown here are mean (SEM) values obtained from 5 mice in each group.
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gen-specific T cell response.
Our results suggest that primary DCs are morphologi-
cally similar to JAWS II DCs under resting conditions
(non-transfected). At phenotypic level, we found that
the primary DCs were mainly of myeloid DC type, like
JAWS II DCs, but there were slight differences in the
expression pattern of certain cell-surface markers. For
instance, the expression of CD11c, MHC class II and
CD80 (all myeloid-specific markers) was more pro-
nounced on the cell-surface of primary DCs as com-
p a r e dt oJ A W SI ID C s( F i g u r e3 ) .T h ed i f f e r e n c ei n
expression pattern of myeloid DC-specific markers may
be due to the differences in culture conditions. As noted
above, JAWS II DCs were maintained in culture med-
ium containing GM-CSF only, whereas the primary DCs
were cultured in the presence of GM-CSF as well as IL-
4. Earlier, Jiang et al., found similar differences in the
expression of CD11c, MHC II and CD80 between rest-
ing JAWS II DCs and C57BL6 mice-derived primary
DCs [29].
Under in vitro culture-conditions, the DCs mature
over a period of time [8,30]. Thus, the timing of DC cul-
ture and harvest needs optimization on case-by-case
basis. Since we did not observe any significant difference
between the antigen presenting ability of the 2dDC and
the 4dDC, we used 2dDC for genetic transfection and
i m m u n i z a t i o n .W ea l s oo b s e r v e dt h a tC D 1 1 c ,M H C
class II and T cell co-stimulatory molecules (CD40,
CD80 and CD86) continued to increase in primary DCs
from day 2 to 4. Based on these comparisons of pheno-
typic and functional analysis, we chose 2dDCs for anti-
gen-presentation and downstream in vivo immunization
experiments. We believe that it may ultimately be bene-
ficial in clinical scenarios to obtain the starting material,
i.e., primary DCs within 2 days of seeding the bone mar-
row cells in DC-promoting culture conditions.
We further studied the functional activity of primary
DC-vaccine by DC: T cell co-culture assay. The activa-
tion of autologous CD4+ and CD8+ T cells was evident
in co-culture assays (Figure 8). However, the expression
of CD25 and CD69 was more pronounced in CD4+ and
CD8+ T cells co-cultured with C57BL6-derived JAWS II
vaccine as compared to BALB/c-derived DC- vaccine.
We were intrigued by this finding and decided to
explore the cytokine secretion. We observed no signifi-
cant difference in cytokine (TNF-a, IL-6, IL-10, IL-12)
secretion by pVR1012-Ag2/PRA-cDNA transfected pri-
mary DCs as compared to similarly transfected JAWS II
DCs. It is however, apt to mention that we, and others,
have found significant differences in DC-responses
against Coccidioides in different mouse strains, specifi-
cally BALB/c versus DBA/2 and C57BL6 versus DBA/2
[8,9]. Differences in immune responses elicited by
different immunization strategies against Mycobacterium
tuberculosis [31] and Porphyromonas gingivalis [32,33]
have also been reported in C57BL6 and BALB/c mouse
strains. It appears that host genetic factors may be
responsible for the differences in antigen-recognition
and immune responses in the two mouse strains.
The entire in vitro work discussed thus far pointed
towards an effective primary DC vaccine. The first step
to realizing this in vivo is to study the distribution and
homing of DCs in appropriate tissues and activation of
antigen-specific immune response. To accomplish their
biological functions, the DCs undergo a complex pattern
of migration which includes their localization to both
peripheral non-lymphoid tissues and secondary lym-
phoid organs. In the absence of correct tissue localiza-
tion, the DCs fail to promote proper immune responses
[34-37]. Thus, we studied the trafficking and homing
pattern of primary DC-vaccine in BALB/c mouse strain.
The short-term trafficking aspect has already been
addressed for a C57BL6-derived JAWS II vaccine in a
syngeneic C57BL6 mouse model in our earlier study
[23]. In our published study, we labeled the JAWS II
vaccine with
111In radionuclide and followed the traf-
ficking of cells for a period of 72 h using SPECT (Single
photon emission computer tomography). However, we
noted some technical limitations with
111In-SPECT for
DC-trafficking. One, it does not ensure the integrity of
radiolabel and DC association in vivo, second the resolu-
tion is poor, and lastly it allows imaging only up to 3-4
days. To overcome these limitations, here we used a
molecular PET imaging approach. This is the first time
we have been able to study DC-trafficking in vivo up to
7 days of administration. Similar approach however, has
been used for imaging the migration of other immune
cells and stem cells over a period of 28 days [38-41].
The PET-CT images and the subsequent biodistribution
studies suggested that after intranasal administration,
significant number of DCs accumulate in lung, thymus
and blood. Although the life-span of endogenous DCs is
believed to be short, it is not exactly known how long
the DCs survive in vivo after administration [42-44].
Our results suggest a likelihood that the primary DC-
based vaccine can circulate in the body for at least 7
days of immunization.
Finally, we questioned if the homing of intranasally-
administered DC-based vaccine in lung and lymphoid
organs is sufficient to induce antigen-specific T cell
response and memory. Sufficient evidence exists to sup-
port the fact that generation of immunological memory
is important for a long-term protection [45,46]. Using a
multi-color flow-cytomteric approach, we found a con-
sistent increase in the number of CD4+ and CD8+ TEM
cell population in vaccinated mice suggesting that the
DC-vaccine induces an immunological memory. Since
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dynamic process and involves multiple steps, our efforts
will be to investigate the time-dependent analysis of
memory T cell distribution. The increased secretion of
IFN-g by lung and lymph node cells correlates well with
our previously published results on increased levels of
IFN-g in lung tissue homogenates of DC-vaccinated,
Coccidioides-protected mice [23]. Our findings may have
direct clinical relevance because the reduced levels of
IFN-g cytokine and T cell anergy are associated with
disseminated coccidioidomycosis in human patients and
animal models [5,47].
Conclusions
Overall, our results suggest that the primary DC-vaccine
c a nb ep r e p a r e db yu s i n gas i m p l em e t h o do fn o n v i r a l
genetic-transfection, first developed in our laboratory
[22,23]. After intranasal administration, the DC-vaccine
migrates to both lymphoid and non-lymphoid organs,
induces antigen-specific Th1 response, and generates
memory T cells. Efforts are underway to further evaluate
maintenance of immune responses and memory on
long-term basis and efficacy of DC-vaccine in Cocci-
dioides infection model in BALB/c mouse strain. As
described earlier, the Coccidioides-specific DC responses
and resulting T cell functions are disabled in the BALB/
c mouse strain making them highly susceptible to Cocci-
dioides infection [8]; the adoptive transfer of DC-vaccine
may restore the immunocompetence and contribute to a
protective T cell response in infection model.
Methods
Mice
We used six weeks old female BALB/c and C57BL6 mice
(Jackson Laboratories, ME). All procedures, involving
animals, were approved by the Institutional Animal Care
and Use Committee of the University of Oklahoma
Health Science Center. An acclimatization period of one
week was allowed to the animals prior to any experiment.
Culture of murine bone marrow-derived primary DCs and
JAWS II DCs
Primary DCs were obtained by culturing the murine
bone marrow cells that were harvested as per the
method described earlier [8,48]. The harvested bone
marrow cells were cultured in RPMI 1640 medium
(Gibco Life Sciences, NY) containing 10 mM N-2-
Hydroxyethylpiperazine-N’-2-ethanesulfonic acid
(HEPES), 10 μg/ml gentamicin, 100 U/ml penicillin, 100
μg/ml streptomycin, 10% fetal bovine serum (FBS), 1%
MEM nonessential amino acids, 50 μM b-mercaptoetha-
nol, 10 ng/ml recombinant mouse-GM-CSF and 10 ng/
ml recombinant mouse-IL-4 (both cytokines from
Peprotech, NJ). The cells wer ei n c u b a t e da t3 7 ° Ci n5 %
CO2 atmosphere and the DCs were harvested either on
day 2 or day 4 on Optiprep density gradient solution
(Accurate Chemicals, NY) [30]. Briefly, nonadherent
cells were collected, washed and subjected to density
gradient separation. The DCs were isolated as floating
cells from the top layer (density < 1.065 g/ml) of the
Optiprep density gradient.
JAWS II cells are an immortalized immature myeloid
DC cell line derived from the bone marrow of p53-/-
C57BL6 mice. We obtained JAWS II cells from ATCC,
VA, and maintained them in complete Alpha MEM
medium containing 20% FBS, 5 ng/ml GM-CSF and
antibiotics [22,23].
Isolation of splenic lymphocytes
The lymphocytes were isolated from murine spleen using
Lympholyte-M solution (Cedarlane, Canada) as per the
manufacturer’s instructions. Briefly, spleen was minced
between two sterile glass slides, and a single cell suspen-
sion was obtained by passing the minced spleen through
a nylon filter (BD Biosciences, CA). Five ml of the splenic
cell suspension (~1 × 10
7 cell/ml in Hanks balanced salt
solution) was layered over 5 ml of Lympholyte M and
centrifuged for 20 min at 1000-1500 × g. After centrifu-
gation, the lymphocytes were collected from the interface
and washed twice, prior to further analysis.
The viability of cells was determined by standard try-
pan blue dye exclusion test. The cell morphology was
observed by staining the air-dried cells with Diff-Quik
stain (Dade Behring, IL).
Preparation of Plasmid DNA clones
A plasmid DNA clone encoding full-length Coccidioides-
Ag2/PRA-cDNA (pVR1012-Ag2/PRA) was used. We
also included pHYG-EGFP (BD Biosciences Clontech,
Palo Alto, CA) for measuring the transfection efficiency.
In addition, we prepared a plasmid pVR1012-TK clone
that carried HSV-1 encoded thymidine kinase (TK). The
HSV-1-TK insert was amplified from the pMOD-TK
(Invivogen, CA; with low CpG content) using forward
primer 5’AAAACTCGAGTCACTATAGGAGGGC-
CACCA3’ carrying the PstI restriction site and reverse
primer 5’AGCAAAAAAAGCTCAGCA3’ carrying the
BamHI restriction site. The PCR amplified HSV-1 TK
insert was digested with BamHI and PstI restriction
enzymes and subcloned into the pVR1012 vector plas-
mid DNA (Vical, CA) to obtain pVR1012-TK. The sub-
cloning of the TK insert (1149 bp) was confirmed by
restriction digestion. The in-frame cloning was con-
firmed by sequencing the pVR1012-TK plasmid DNA
clone at the Sequencing facility (Oklahoma Medical
Research Foundation, Oklahoma City, OK). The endo-
toxin-free plasmid DNAs were prepared using Endo-free
Maxiprep kit (Qiagen, CA).
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The primary DCs (2dDC harvested on day 2 and 4dDC
h a r v e s t e do nd a y4o fc u l t u r e )a n dJ A W SI ID C sw e r e
washed with serum free Dulbecco’s minimum essential
medium (DMEM; Invitrogen, CA) before transfection. A
non-viral, lipid-based transfection reagent: TransIT-TKO
(Mirus Bio, WI) was used. The transfection reagent-DNA
complex (4 μl:2 μg of each plasmid DNA) was prepared
in DMEM medium by adding plasmid DNAs (2 μg
pHYG-EGFP or 2 μg pVR1012-VP22 vector plasmid
DNA or 2 μg pVR1012-Ag2/PRA-cDNA ± 2 μg
pVR1012-TK) to the TransIT-TKO reagent. The cells
were incubated with the lipid/DNA mixture at 37°C in
5% CO2 incubator. The percent transfection efficiency
was evaluated by visual enumeration of the green fluores-
cent transfected cells versus total number of cells using a
fluorescent microscope with appropriate filter (Olympus
Optical Co. Ltd, Tokyo, Japan). The viability of trans-
fected cells was assessed by flow cytometry after staining
the cells with propidium iodide (1 μg/ml).
The protein expression of Ag2/PRA and HSV-1 TK in
co-transfected cells was studied by dot-immunoblotting
with Ag2/PRA- and TK-specific antibody (Santacruz Bio-
tech, CA), respectively [22]. The recombinant Ag2/PRA
protein served as a control. The recombinant Ag2/PRA-
protein and specific antibody were obtained from
Dr. John Galgiani (University of Arizona, Tucson, AZ).
The HSV-1 TK antibody (Santacruz Biotech, CA) was
specific to a peptide mapping near the N-terminus of
HSV1-TK.
Flow cytometry
Dendritic cells, cells from DC-lymphocyte co-culture
experiment, or splenic lymphocytes, thymocytes or
lymph node cells harvested from vaccinated mice were
washed twice with Dulbecco’s phosphate-buffered saline
(D-PBS) and suspended to a concentration of 1 × 10
6
cells in 100 μl D-PBS containing 1% FBS for staining
with appropriate fluorochrome-conjugated antibodies
(Table 2). After 30 min of incubation with antibodies,
the cells were washed. The cells stained with biotin-con-
jugated antibodies were further incubated with streptavi-
d i n - A P Co rs t r e p t a v i d i n - PE-texas red conjugate for
20 min. Depending on the number of fluorochromes,
the cells were assayed either with a FACS Calibur or
Influx flow cytometer (BD Biosciences, CA). The appro-
priate isotype-matched control antibodies were used to
determine the levels of background staining. The histo-
gram and dot plot data were collected and analyzed
using either Summit v 4.3 (Dako Colorado Inc, CO), or
FlowJo software (Flow Jo, OR) programs. We gated the
positive cells in the histogram charts and obtained mean
fluorescent intensity (MFI) values.
DC-lymphocyte co-culture experiment
For the DC-lymphocytes co-culture experiments, the DC
to splenic lymphocytes ratios and time of incubation
were optimized in the pilot experiments. Finally, in the
comprehensive experiments, the nontransfected and
transfected DCs (2dDC and 4dDC) were co-cultured
with splenic lymphocytes (1 DC: 64 T cells) for a period
of 24 h. The activation of T cells was determined on the
basis of staining of cells with CD4, CD8 (T cell markers),
CD25 and CD69 (activation markers)-specific antibodies.
Cytokine analysis in cell-free supernatants of DCs
The cell-free supernatants collected from pVR1012-Ag2/
PRA-cDNA-transfected and non transfected cells were
analyzed for the secreted cytokines. The amounts of cyto-
kines: tumor necrosis factor (TNF)-a, interleukin (IL)-6,
IL-10, IL-12p70 and interferon (IFN)-g, were measured in
cell-free supernatants using mouse inflammation cyto-
metric bead array kit (BD Biosciences, CA). Briefly, 50 μl
of 1:10 and 1:100 diluted cell-free supernatants and
diluted cytokine standard solutions (20-2500 pg/ml) were
mixed with 50 μl of cytokine capture antibody mix and
50 μl of PE detection reagent. The reaction mixtures
were incubated for 2 h, washed and resuspended in wash
buffer. The samples were then assayed on FACS Calibur
flow cytometer. The acquired data were analyzed for the
amounts of cytokines in samples with the BD Cell Quest
and CBA Array software programs.
Monitoring of primary murine DC-based vaccine by PET-
CT imaging
In order to study the in vivo trafficking of primary DCs,
the cells were co-transfected with pVR1012-Ag2/PRA-
cDNA and pVR1012-TK. The transfection protocol
remained identical to that described above. The
molecular imaging technique was based on the use of
Table 2 List of fluorochrome-conjugated antibodies
Cells Fluorochrome-conjugated antibodies for staining DC or lymphocytes
DCs Fluorescein isothiocyanate-conjugated (FITC)-CD14, CD3, CD86, CD62L; phycoerythrin (PE)-CD11c, CD45R,
CD80, PDCA-1; Biotin or allophycocyanin (APC)-CD40, MHC class II (I-A/I-E), 120G8 and B220.
Cells from DC-lymphocyte co-culture FITC-CD69, PE- CD8b (Ly-3), APC-CD4, PerCP-Cy5.5-CD25.
Splenic lymphocytes, thymocytes and
lymph node cells
FITC- CD69, PE-CD127, Pacific orange-CD4, APC-CD8, PerCpCy5.5-CD25, Pacific blue-CD44, APC-Cy7-CD62L,
Biotin-CCR7
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iodouracil (FIAU), a specific substrate for HSV1-TK.
The cells expressing HSV1-TK phosphorylate
18F-FIAU
to phospho-
18F-FIAU, which is then incorporated, thus
trapped, in the DNA and detected by PET system. Since
untransformed mammalian cells do not express TK
enzyme, normal mammalian cells do not phosphorylate
FIAU, and therefore, are unable to entrap the probe and
generate PET signal.
Radiofluorination to synthesize
18F-FIAU
The PET imaging probe,
18F-FIAU was prepared as
described earlier [21-23]. The fluorine-18 (
18F) was pro-
duced by the (p, n) nuclear reaction on oxygen-18 (O-
18)-enriched water with 11 MeV protons in an RDS-112
cyclotron (Midwest Medical Isotopes, Oklahoma City).
The FIAU precursor (1) was prepared using following
synthetic steps [22]. The syn t h e t i cs c h e m ef o rg e n e r a t -
ing
18F-FIAU as well as the precursor chemicals is
shown in Figure 13 and described below.
2-Deoxy-2-[
18F]-fluoro-1,3,5-tri-O-benzoyl-a-D-
arabinofuranose (2)
In a reaction vial containing 500 μl of Kryptofix solution
(12 mg/ml), about 15 μlo fK 2CO3 (100 mg/ml) was
added. The
18F-fluoride radioactivity was added to the
reaction vial and the mixture was evaporated to dryness
at 160°C under nitrogen gas. Azeotropic evaporation
was performed with acetonitrile to remove all traces of
water. The chemical precursor, 2-O-[(trifluoromethyl)
sulfonyl]-1,3,5-tri-O-benzoyl-a-D-ribofuranose (1)i n
dimethylformamide (10 mg in 250 μl) was added to the
reaction vial. The reaction mixture was heated at 160°C
for 8 min. The reaction vial was transferred to a heated
block (110°C), and the solvent was evaporated to about
50 μl under nitrogen. The vial was cooled to room tem-
perature and dichloromethane (DCM, 5 ml) was added
to the vial. The solution was then passed through a Sep-
Pak silica cartridge (ChromTech, IL) to remove
unreacted
18F-fluoride. The
18F-labeled compound 2 was
obtained in the DCM eluate with 50% radiochemical
yield (RCY).
1-(2’-Deoxy-2’-[
18F]-fluoro-3,5-di-O-benzoyl-D-
arabinofuranosyl) pyrimidines (3)
The DCM solution of compound 2 was dried under
nitrogen, and the residue was re-dissolved in chloroform
(200 μl). To the solution of 2, 2,4-bis-O-(trimethylsilyl)-
5-iodouracil (200 μl of 0.252 M solution in acetonitrile),
trimethyltrifluromethane sulfonate (20 μl) and bis-(tri-
methylsilyl)trifluoro acetamide (20 μl) were added. The
reaction mixture was heated at 100°C for 30 min, and
passed through Sep-Pak silica cartridge to obtain com-
pound (3) as isomeric mixture in chloroform.
1-(2’-Deoxy-2’-[
18F]-fluoro-D-arabinofuranosyl)
pyrimidines (4)
Compound 3 was dried and the residue was added with
acetonitrile (500 μl) and 250 μlo fs o d i u mm e t h o x i d e
(0.5 N) solution The mixture was heated at 100°C for 10
min, and the alkalinity was neutralized by adding 1.0 ml
of 0.1% acetic acid. The de-protected
18F-FIAU was
obtained by passing the mixture through a Sep-Pak C-
18 column to collect the
18F-FIAU as a combination of
a and b isomers. The isomeric mixture was concen-
trated and injected into an HPLC column (Phenomenex
Luna column, 5 μm, 250 × 4.6 mm). Pure b-isomer of
18F-FIAU was collected as a peak with retention time of
9.8 min using a gradient system (5% to 100% acetonitrile
in water over 25 min) at 254 nm wavelength. The pro-
duct (Compound 4) was dried and dissolved in saline
with an overall RCY of 30-35%, and >95% radiochemical
purity. The purity of the product was confirmed by
injecting a small fraction of the finished product into an
analytical HPLC, and spiking it with authentic FIAU
(Moravek Biochemicals, Brea, CA).
Measurement of HSV1-TK enzyme activity in transfected
cells
Prior to in vivo imaging, we measured the TK enzyme
activity in pVR1012-TK-transfected DCs using following
methods.
HSV1-TK enzyme activity assay
The HSV1-TK enzyme activity was determined in
pVR1012-TK transfected JAWS II DCs using
18F-
FIAU as well as standard
3H-pencyclovir as substrates
[49]. After 48 h of transfection, the transfected cells
were lysed in a buffer containing 10 mM Tris-HCl, 3
mM of b-mercaptoethanol (Invitrogen-Gibco, CA),
0.5% Igepal CA-630, 25 mM sodium fluoride (Strem
Chemicals, MA). The total protein in the cell lysate
was analysed using bicinchonic acid protein assay kit
(Pierce, IL). About 50 μg of total cell lysate protein
Figure 13 A detailed schematic of
18F-FIAU synthesis for molecular imaging of DC distribution by PET.
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NaH2PO4.H 2O, pH 6.0 and 0.024 M ATP, pH 7.0)
containing 150 μCi of
18F-FIAU, or 20 μCi of
3H-pen-
cyclovir. The enzymatic reaction was allowed to occur
at 37°C for 20 min. The reaction was stopped by add-
ing ice-cold water. An aliquot (40 μl) of this reaction
mixture was then blotted on Whatman DE81 filters
(VWR, PA) and allowed to settle for 1 min. The filters
were washed with a solution containing 4 mM of
ammonium formate and 10 μMo ft h y m i d i n ei n9 5 %
ethanol. Finally, the dried-filters were placed in vials
with (
3H) or without (
18F) scintillation fluid and radio-
active counts (counts per min; cpm) were read on a
Cobra II Autogamma counter (Packard Biosciences,
CT) or Beckman Coulter LS6500 (Beckman Coulter,
CA). Percent probe phosphorylated was calculated
using the following equation:
Percent probe phosphorylated per  g per min
Total cpm Bac
m
=
− (k kground cpm
Protein  g Reaction Time cpm in  l HSV -TK 
)
( mm ×× 31 R Reaction Buffer)
×100
Uptake of
18F-FIAU by pVR1012-TK-transfected DCs [49-51]
After 48 h in transfection, the cells were washed with
Dulbecco’s PBS and incubated with 25 μCi
18F-FIAU in
a- MEM medium without FBS at 37°C in 5% CO2 incu-
bator. After 4 h incubation, cell-free medium was col-
lected. The cells were washed with PBS and harvested in
100 μl of 0.1 M NaOH. The cell-associated and medium
supernatant-associated radioactivity (cpm) was counted
in Cobra II Autogamma gamma counter (Packard Bios-
ciences, Meridian, CT). Percent uptake was normalized
with the total number of cells in each well and calcu-
lated using the following formula:
Percent Uptake
Cell-associated cpm
Cell-associated cpm M
=
+
()
( e edium-associated cpm)
×100
Intranasal immunization of syngeneic mice with primary
DCs
The cells were transfected with pVR1012-Ag2/PRA-
cDNA and pVR1012-TK plasmid DNAs, as described
above. After 24 h of transfection, the syngeneic BALB/c
mice were immunized with transfected DCs (1-1.5 × 10
6
DCs suspended in sterile, low-endotoxin 30-40 μlP B S
per mouse) via intranasal route [23]. The control mice
received DCs transfected with a vector plasmid DNA.
PET-CT imaging
The PET-CT imaging was performed on vaccinated
mice on days 2 and 7 of immunization. Radiolabeled
18F-FIAU was intravenously injected in mice via tail
vein. The probe was allowed to distribute for 2 h
before PET-CT imaging was performed. Mice were
anesthetized with 2% isoflurane in an oxygen stream
and positioned in the field of view (FOV) of X-PET/
X-O-CT machine (Gamma Medica-Ideas, Northridge,
CA). A fly-mode CT was acquired (2 min) to establish
anatomical landmarks before re-positioning the ani-
mal for PET imaging. About 20 min list-mode PET
data was acquired. The acquired image data were
reconstructed using filtered back projection algo-
rithm. Both PET and CT images were fused together
using Amira 3.1 software provided with the imaging
system.
Biodistribution of
18F radioactivity
Mice were euthanized 140 min after injecting
18F-FIAU,
and various organs and/or tissues (heart, lung, liver,
spleen, stomach, intestine, kidney, blood, etc.) were
excised under aseptic conditions. The organs were
weighed, and the associated
18F radioactivity was
counted in an automated gamma counter (Cobra II, Per-
kin-Elmer). The organ-associated counts were expressed
as percent of injected dose per gram of tissue.
T cell phenotype and Ag2/PRA-specific response in DC-
vaccinated mice
In a separate set of DC-vaccinated mice, the lung, thy-
mus, spleen and lymph nodes (superficial cervical, axil-
lary, brachial and inguinal) were harvested on day 7 and
lymphocytes were isolated using Lympholyte M density
gradient solution as described above.
The splenic lymphocytes, thymocytes and lymph node
cells were stained with antibodies conjugated to 8 differ-
ent fluorochromes (Table 2). Single fluorochrome-conju-
gated stained lymphocytes were used for appropriate
gating and to confirm no spill over. The T cell pheno-
type was then studied by flow cytometry. The percent
number of CD4+ and CD8+ central memory (TCM)a n d
effector memory (TEM) populations were noted on the
basis of expression of CD62L and CCR7.
The T cell response against Ag2/PRA protein was
assessed using ELISPOT assay as per the manufacturer’s
instructions (eBioscience, CA). Briefly, the wells of PVDF
membrane ELISPOT assay plates (Millipore, CA) were
coated with capture antibody to IFN-g,I L - 4o rI L - 1 7 A .
The cells were seeded onto the antibody-coated wells at
the density of 0.8-32 × 10
6 cells/ml and incubated in
RPMI medium containing 10% FBS and antibiotics for 48
h in presence of recombinant Ag2/PRA (1 μg/ml). Subse-
quently, the biotinylated detection antibody, streptavidin-
horse-radish-peroxidase conjugate and substrate solution
were added, and development of spots was monitored.
The wells were washed and air-dried. The spots were
counted using a dissecting microscope. The frequency of
cytokine-secreting, antigen-specific cells on the filtration
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presence of Ag2/PRA minus the number of spots per
equal number of cells in medium alone. Finally, the num-
bers of cytokine secreting cells harvested from mice
immunized with vector plasmid DNA transfected DCs
were subtracted from those in DC-vaccinated mice.
Statistics
The results were analyzed by Student t-test for statistical
significance using Prism software (Graphpad, San Diego,
CA). The significant difference between the experimen-
tal and control groups was noted at p < 0.05.
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